Drugs / Ipratropium
Ipratropium
also known as
ipratropium bromide · ATROVENT · Atrovent aerocaps · Atrovent fte · Atrovent HFA · Atrovent udvs · AtroventTM · Bromure d'ipratropium · +17 more
Small molecule targets CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | ATROVENT | — | 1998-04-01 – 2000-10-27 | fda.gov ↗ |
| Approved | US (FDA) | ATROVENT | — | 1986-12-29 | fda.gov ↗ |
Trials 64 · started per year
today
US approved 1986
1
9
2
3
1
8
3
4
1
4
2
1
1
1
2
2
2
1
5
3
1
1
2
3
1
198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04617015 | Sep 2016 → Mar 2019 | childhood onset asthma, depressive disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT03480997 | Dec 2016 → Apr 2017 | chronic obstructive pulmonary disease | Pneuma Respiratory, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02872597 | Sep 2016 → Aug 2018 | status asthmaticus | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02207452 | Aug 2010 → Jul 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00549120 | Aug → Oct 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02172781 | Jan → Apr 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02173678 | Oct → Nov 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02755714 | Jun 2016 → Oct 2020 | — | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 212 trials · 2 met primary | ||||||
| Phase 2 | NCT07394036 | Jun 2026 → Dec 2029 expected | — | Cook Children's Health Care System | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06074185 | Jan 2024 → Feb 2025 | childhood onset asthma | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT03747536 | Jan → Oct 2019 | — | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 2 | NCT02542254 | Oct → Dec 2015 | chronic obstructive pulmonary disease | Verona Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03064113 | May → Oct 2011 | chronic obstructive pulmonary disease | Mylan Inc. | Completed | Met primary |
| Phase 2 | NCT00818454 | Dec 2008 → Sep 2009 | asthma | Boehringer Ingelheim | Completed | Met primary |
| Phase 2 | NCT00296946 | Nov 2004 → Jun 2006 | Parkinson disease | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00096616 | Nov 2004 → Mar 2006 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02182674 | Oct 2000 → Aug 2001 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02236169 | Oct 2000 → Apr 2001 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02260011 | Oct 2000 → Feb 2001 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02236182 | Jul 1998 → Feb 1999 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 319 trials · 1 met primary | ||||||
| Phase 3 | NCT05890638 | Aug 2023 → Feb 2024 | chronic obstructive pulmonary disease | Neutec Ar-Ge San ve Tic A.Ş | Unknown | No outcome recorded |
| Phase 3 | NCT04446637 | Sep 2021 → Sep 2022 | chronic obstructive pulmonary disease | Neutec Ar-Ge San ve Tic A.Ş | Withdrawn | No outcome recorded |
| Phase 3 | NCT02782052 | Jul 2016 → Oct 2018 | pulmonary arterial hypertension | Assistance Publique - Hôpitaux de Paris | Withdrawn | No outcome recorded |
| Phase 3 | NCT01944033 | Jul 2013 → Jul 2016 | chronic obstructive pulmonary disease | University of Monastir | Completed | No outcome recorded |
| Phase 3 | NCT00462540 | May → Sep 2007 | chronic obstructive pulmonary disease | Dey | Completed | Met primary |
| Phase 3 | NCT00239434 | Jun 2003 → Mar 2004 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02176187 | Apr 2003 → Dec 2004 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT02176200 | Apr 2003 → Dec 2004 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT02177253 | Oct 2002 → Mar 2004 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02173795 | Oct 2002 → Jun 2003 | asthma, chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00274066 | Oct 2002 → Sep 2003 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00274092 | Sep 2002 → Oct 2003 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00274040 | Jul 2002 → Mar 2003 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02182505 | Sep 1998 → Jul 1999 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02177344 | Aug 1998 → Oct 1999 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02182700 | Jul 1998 → Dec 1999 | asthma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT02182479 | Apr 1998 → Jun 1999 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02173782 | Feb 1998 → Apr 1999 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00000568 | Sep 1984 → Jan 2005 | chronic obstructive pulmonary disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 414 trials · 2 met primary | ||||||
| Phase 4 | NCT06825013 | Nov 2024 → Jan 2027 expected | chronic obstructive pulmonary disease | Dr. J. Alberto Neder | Recruiting | No outcome recorded |
| Phase 4 | NCT06918418 | Jan → Jun 2024 | acute asthma | Children's Hospital and Institute of Child Health, Multan | Completed | No outcome recorded |
| Phase 4 | NCT03219866 | Oct 2017 → Apr 2020 | chronic obstructive pulmonary disease | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01943552 | Oct 2013 → Jul 2015 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | Met primary |
| Phase 4 | NCT02103374 | Jan 2012 → Dec 2015 | chronic obstructive pulmonary disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 4 | NCT00388882 | Oct 2006 → Oct 2007 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00359788 | Jul 2006 → Apr 2008 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | Met primary |
| Phase 4 | NCT00354354 | Mar 2006 → Jul 2009 | chronic obstructive pulmonary disease | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT00202176 | Jul 2005 → Dec 2008 | chronic obstructive pulmonary disease | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT02238210 | Dec 2002 → May 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00273962 | May 2002 → Nov 2003 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02235428 | Sep 1998 | asthma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 4 | NCT02182713 | May → Sep 1998 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02182856 | Feb 1998 → Jul 2000 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable11 trials · 1 met primary · 1 missed | ||||||
| — | NCT05786950 | Jan → Jul 2023 | chronic obstructive pulmonary disease | The First Affiliated Hospital of Guangzhou Medical University | Completed | No outcome recorded |
| — | NCT03071731 | Apr 2017 → Jun 2019 | chronic obstructive pulmonary disease | Laval University | Unknown | No outcome recorded |
| — | NCT03271905 | Apr 2017 → Dec 2018 | asthma, chronic obstructive pulmonary disease | Federal University of Rio Grande do Norte | Unknown | No outcome recorded |
| — | NCT02296047 | Dec 2014 → May 2015 | chronic obstructive pulmonary disease | Zhujiang Hospital | Completed | No outcome recorded |
| — | NCT03062904 | Feb 2014 → Dec 2019 | — | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT01655199 | Sep 2012 → Jul 2014 | chronic obstructive pulmonary disease | Laval University | Unknown | No outcome recorded |
| — | NCT00381589 | Oct 2006 → Jun 2008 | — | Centre for Addiction and Mental Health | Completed | Missed primary |
| — | NCT00498251 | Sep 2004 → Jun 2007 | acute lung injury | University Hospital, Geneva | Completed | No outcome recorded |
| — | NCT00583778 | Aug 2004 → Nov 2008 | asthma | MetroHealth Medical Center | Completed | Met primary |
| — | NCT00371527 | Oct 2002 → Jan 2004 | bronchitis | Kaiser Permanente | Completed | No outcome recorded |
| — | NCT00904436 | Dec 1999 → Jan 2001 | quadriplegia | US Department of Veterans Affairs | Completed | No outcome recorded |
| Comparator or background therapy37 trials | ||||||
| Phase 1/2 | NCT06657079 Comparator | May 2024 → Jan 2025 | acute respiratory distress syndrome | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT04315558 Comparator | Nov 2020 → Jan 2025 | acute respiratory failure, chronic obstructive pulmonary disease | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT01426009 Comparator | Aug → Dec 2011 | chronic obstructive pulmonary disease | Sunovion Respiratory Development Inc. | Completed | Met primary |
| Phase 2 | NCT01350128 Comparator | May → Oct 2011 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT00117182 Background | Jul 2005 → Aug 2006 | chronic obstructive pulmonary disease | Syntara | Completed | No outcome recorded |
| Phase 2/3 | NCT06376942 Comparator | Apr 2024 → Apr 2025 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT06040424 Comparator | Sep 2023 → Jun 2024 | chronic obstructive pulmonary disease | Neutec Ar-Ge San ve Tic A.Ş | Unknown | No outcome recorded |
| Phase 3 | NCT01987219 Comparator | Mar 2013 → Dec 2014 | Riley-Day syndrome | NYU Langone Health | Completed | No outcome recorded |
| Phase 3 | NCT01019694 Comparator | Nov 2009 → Apr 2011 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00588406 Background | Sep 2007 → Dec 2009 | asthma | Northwell Health | Completed | No outcome recorded |
| Phase 3 | NCT01136421 Comparator | Jan 2005 → Jun 2007 | chronic obstructive pulmonary disease | University of Monastir | Completed | No outcome recorded |
| Phase 3 | NCT02172443 Comparator | Jun 2001 → May 2002 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02172469 Comparator | May 2001 → Apr 2002 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT04655170 Comparator | Dec 2020 → Jan 2023 overdue | chronic obstructive pulmonary disease | University of Tennessee Graduate School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT04167280 Comparator | Nov 2019 → Mar 2020 | asthma | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT03738917 Comparator | Feb 2019 → Nov 2021 | bronchitis | Jordi Gol Institute for Primary Care Research | Completed | No outcome recorded |
| Phase 4 | NCT03405090 Comparator | Sep 2017 → Mar 2022 | chronic obstructive pulmonary disease | Dr. Denis O'Donnell | Completed | No outcome recorded |
| Phase 4 | NCT02584738 Background | Sep 2015 → Jan 2016 | asthma | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 4 | NCT01691079 Comparator | Dec 2012 → Dec 2014 | exercise-induced bronchoconstriction | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT01696214 Comparator | Oct 2012 → May 2015 | asthma | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01691482 Comparator | Jul → Oct 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01415518 Background | Sep 2011 → Dec 2012 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Met primary |
| Phase 4 | NCT00911651 Comparator | Jun → Jul 2008 | chronic obstructive pulmonary disease | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT00605410 Comparator | Jan → Apr 2008 | asthma | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT00460577 Comparator | Mar 2007 → Sep 2008 | acute asthma | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00393367 Background | Dec 2006 → Nov 2007 | acute asthma, reactive airway disease | Children's Hospital of Philadelphia | Completed | Missed primary |
| — | NCT05550402 Comparator | Feb → Jun 2024 | asthma, obstructive lung disease, parasympathetic nervous system disorder | Hat Yai Medical Education Center | Unknown | No outcome recorded |
| — | NCT05183841 Comparator | Apr 2022 → Nov 2024 | bronchiectasis | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT02509299 Background | Sep → Nov 2019 | chronic obstructive pulmonary disease | University of Granada | Completed | No outcome recorded |
| — | NCT03296579 Comparator | Jun → Nov 2018 | acute asthma, childhood onset asthma | University of British Columbia | Unknown | No outcome recorded |
| — | NCT02790047 Background | Oct 2016 → Jan 2018 | chronic obstructive pulmonary disease | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT02686086 Comparator | Feb 2016 → Jul 2017 | chronic obstructive pulmonary disease | Beaumont Hospital | Completed | No outcome recorded |
| — | NCT02515318 Comparator | Sep 2015 → Mar 2017 | chronic obstructive pulmonary disease | University of Granada | Unknown | No outcome recorded |
| — | NCT02458482 Comparator | Jul 2015 → Nov 2020 | asthma | Vanderbilt University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00807534 Comparator | Oct 2008 → Dec 2009 | chronic obstructive pulmonary disease | Laval University | Completed | No outcome recorded |
| — | NCT00521222 Background | Jun 2007 → Nov 2010 | asthma | Columbia University | Completed | No outcome recorded |
| — | NCT00180843 Comparator | Sep 2005 → Feb 2008 | chronic obstructive pulmonary disease | Imperial College London | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2011-10-07 | Boehringer Ingelheim | Regulatory FDA Approves Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease prnewswire.com ↗ |
| 2010-04-13 | Boehringer Ingelheim | Regulatory FDA Maintains Essential Use Status of Combivent(R) (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Through 2013 prnewswire.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ipratropium | “Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand...” NCT01944033 ↗49“50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d” NCT02173782 ↗ “Test of Bronchodilatation (combined Salbutamol 200μg and Ipratropium bromure 80μg; 2 inhalations): wait 30 min and then” NCT03062904 ↗ “Participants will be administered aerosolized budesonide and ipratropium or a placebo every eight hours for five days.” NCT06657079 ↗ “50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide” NCT02182479 ↗ “comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB).” PMID 18403223 ↗ Mar 2008 “All subjects receive inhaled ipratropium once with measurement of spirometry before and after.” NCT04617015 ↗ “0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer” NCT03405090 ↗ “anticholinergic agents (ipratropium and oxitropium bromide)” NCT02515318 ↗ “anticholinergic agents (ipratropium and oxitropium bromide)” NCT02509299 ↗ “fenoterol hydrobromide 50μg + ipratropium bromide 20μg” NCT02176187 ↗ |
| Known as | ATROVENT | “An Open-Label, Crossover, Pharmacokinetic Trial to Determine the Comparability of 84 µg Ipratropium Bromide HFA-134a Inhalation Aerosol to 84 µg ATROVENT® CFC Inhalation...” NCT02236169 ↗13“To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of...” NCT00274066 ↗ “The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation...” NCT02260011 ↗ “Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml.” NCT03271905 ↗ “Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).” NCT00904436 ↗ “20 mcg and 40 mcg of Ipratropium Bromide, as delivered by the RESPIMAT Device, to 18 mcg ATROVENT® Inhalation Aerosol” NCT02177344 ↗ “Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care” NCT04655170 ↗ “Atrovent? MDI (2 puffs of ipratropium bromide 20 ?g four times daily)” NCT00239434 ↗ “(Atrovent ®)” NCT01987219 ↗ |
| Known as | Atrovent aerocaps | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Atrovent fte | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Atrovent HFA | “Ipratropium bromide (Atrovent® HFA) is a short acting anticholinergic bronchodilator (short acting muscarinic antagonist (SAMA)) that improves lung function, dyspnea, exercise...” NCT00911651 ↗ |
| Known as | Atrovent udvs | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | AtroventTM | “ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)” NCT01415518 ↗ |
| Known as | Bromure d'ipratropium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Bromuro de ipratropio | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratrop | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratrop steripoule | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | ipratropium bromide | “Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to...” NCT02182674 ↗55“Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and...” NCT02176200 ↗ “This study's objective was to evaluate whether ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI) provides more effective acute relief of bronchospasm in...” PMID 27130202 ↗ Apr 2016 “Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml.” NCT03271905 ↗ “the simultaneous administration of ipratropium bromide hydrofluoroalkane (HFA; I) and albuterol HFA (A) metered-dose inhalers as dual monotherapies (I + A).” PMID 23658479 ↗ Mar 2013 “The bronchodilator consisted of ipratropium bromide prescribed three times daily, two puffs per time, from a metered-dose inhaler.” NCT00000568 ↗ “inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)” NCT05786950 ↗ “Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test” NCT03071731 ↗ “Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)” NCT02173795 ↗ “0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer” NCT03405090 ↗ “Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care” NCT04655170 ↗ |
| Known as | Ipratropium bromide anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium bromide component of combivent | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium bromide component of duoneb | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium bromide component of duovent | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium bromide hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium bromide monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Ipratropium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | NSC-759613 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Respontin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Rinatec | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | SCH 1000-BR-MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | SCH-1000-BR- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Known as | Tropiovent | ChEMBL registry synonym — accepted as the source's own label CHEMBL1621597 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1621597 ↗1“the muscarinic antagonist, ipratropium bromide” NCT00296946 ↗ |
| Modality | Other / unclassified | “short-acting inhaled anticholinergic” NCT04617015 ↗ |
| Modality | Small molecule | — CHEMBL1621597 ↗ |
| Route | Inhaled | “from a metered-dose inhaler” NCT00000568 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1621597 ↗ |